Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Information provided by:
GAAD Medical Research Institute Inc. Identifier:
First received: December 12, 2007
Last updated: March 23, 2009
Last verified: March 2009
A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Condition Intervention Phase
Radiation: Far Infrared Radiation
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.

Resource links provided by NLM:

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:
  • The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 2
Study Start Date: January 2007
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Detailed Description:

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Persons with parathyroid disease

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00573573

Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Study Director: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Chair: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
  More Information

Responsible Party: Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc. Identifier: NCT00573573     History of Changes
Other Study ID Numbers: GAAD-HT-CTP1 
Study First Received: December 12, 2007
Last Updated: March 23, 2009
Health Authority: Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:

Additional relevant MeSH terms:
Parathyroid Diseases
Endocrine System Diseases processed this record on October 25, 2016